HTG2014-Section-Header-publications

Categories

Filter by Topics

ADCC Gene Alteration adolescents ALK Angiogenesis Anti-TNF Alpha Therapy Apoptosis Asthma Autocrine Signaling Autoimmune Disorder B Cells benign Biofluid Biology of neoplasia Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers Bladder Cancer Blood Brain Breast Cancer Breast milk Cancer Genomics Cardiovascular Disease CD3 CDKN2A mutation Cells Cerebrospinal Fluid Chemokines Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs cMET Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy COVID-19 Custom mRNA Cytokines Cytotoxic T Cells Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy epidemiology epigenomics Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E Homing HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immunohistochemistry IHC Immunotherapy Inflammation Integrins Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver liver tissue Lung Lung cancer Lupus Lymph Node Metastasis Lymphocytes Lymphoma machine learning malignant Mechanism of Action Melanoma Mesothelioma MET Method Comparison Microenvironment MicroRNA miRNA Molecular Characterization Mouse mRNA custom mTOR pathway mTOR signaling multi-omics Multiple Myeloma Muscle Mutations MYC NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oncology-Biomarker Oral Cancer Osteoarthritis Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway analysis Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PFAS PIK3CA mutation Placenta placenta Plasma Platform Comparison predictive biology Predictive Biomarkers Predictive Modeling Programmed cell death protein 1 Progression free-survival Prostate Prostate Cancer qNPA qPCR Radioimmunotherapy Rearrangements Renal Cell Carcinoma Renal Disease Reproductive Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Skin SPECS Lung Consortium Squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid synthetic miRNA T-Cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma Uterus VEGFR Wound healing Xenograft Tissue

2020

Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response

Garg, S. K., et al. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers 2020, 12, 3515; doi:10.3390/cancers1213515

Download pdf 3.3MB

2019

Sarcoidosis and Coccidioidomycosis Share Common Tissue Transcriptome Expression Profiles

Casanova, N. G., et al.  Sarcoidosis and Coccidioidomycosis Share Common Tissue Transcriptome Expression Profiles. American Journal of Respiratory and Critical Care Medicine 2019;199:A3079

View External Link

2018

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial

Martin-Broto, J., et al.  Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2018 Dec. http://dx.doi.org/10.1016/S1470-2045(18)30676-4

Download pdf 1.0MB

Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations

Luke J., et al. Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations. Poster session presented at: ESMO 2018 Congress. Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

View External Link

Gene expression difference (GED) revealed immune function gene down-regulation as tumor-associated inflammatory cell (TAIC) infiltration in microenvironment in non-small cell lung cancer (NSCLC)

Wistuba, I., et al, Gene expression difference (GED) revealed immune function gene down-regulation as tumor-associated inflammatory cell (TAIC) infiltration in microenvironment in non-small cell lung cancer (NSCLC). Poster#4054 Presented at American Association for Cancer Research (AACR) Annual Meeting; 2018 Apr 14-18; Chicago, IL

Download ppt 1.9MB
View External Link

Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC).

Galsky, M. et al. Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC). Poster session presented at: Genitourniary Cancers Symposium; 2018 Feb 9; San Francisco, CA. J Clin Oncol 36, 2018 (suppl 6S; abstr 511).

View External Link

Page last updated September 16, 2021